Early diagnosis key to future Alzheimer’s treatmentsThe approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, Share XEarly diagnosis key to future Alzheimer’s treatmentshttps://pharmaphorum.com/r-d/early-diagnosis-key-to-future-alzheimers-treatments/
Thumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumabAfter more than a decade of fraught clinical development it looks like the end of the line for Share XThumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumabhttps://pharmaphorum.com/news/fda-experts-give-thumbs-down-for-pfizer-lillys-painkiller-tanezumab/
US buys Lilly COVID antibody, as effectiveness questions remainThe US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million Share XUS buys Lilly COVID antibody, as effectiveness questions remainhttps://pharmaphorum.com/news/us-buys-300000-doses-lilly-covid-antibody/
Lilly begins trial of COVID-19 antibody treatmentEli Lilly has started dosing patients in the world’s first trial for a medicine specifically designed to attack Share XLilly begins trial of COVID-19 antibody treatmenthttps://pharmaphorum.com/news/lilly-begins-trial-of-covid-19-antibody-treatment/
Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
Lilly’s migraine drug gets key cluster headache approvalThe FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving Share XLilly’s migraine drug gets key cluster headache approvalhttps://pharmaphorum.com/news/lillys-migraine-drug-gets-key-cluster-headache-approval/
Lilly cuts $1bn deal for Centrexion’s non-opioid painkillerEli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront Share XLilly cuts $1bn deal for Centrexion’s non-opioid painkillerhttps://pharmaphorum.com/news/lilly-cuts-1bn-deal-for-centrexions-non-opioid-painkiller/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Pfizer/Lilly non-opioid pain drug shows more positive resultsResults from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can Share XPfizer/Lilly non-opioid pain drug shows more positive resultshttps://pharmaphorum.com/news/pfizer-lilly-non-opioid-pain-drug-shows-more-positive-results/
